- Conditions
- Fuchs Endothelial Corneal Dystrophy, Fuchs
- Interventions
- DT-168
- Drug
- Lead sponsor
- Design Therapeutics, Inc.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • Grand Rapids, Michigan
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 73
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Fuchs' Dystrophy, Corneal Edema
- Interventions
- loteprednol etabonate, prednisolone acetate 1%
- Drug
- Lead sponsor
- Cornea Research Foundation of America
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Corneal Endothelium
- Interventions
- OCT Imaging
- Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Fuchs Dystrophy
- Interventions
- This is an observational study. There is no therapeutic intervention.
- Other
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Aniridia, Eye Abnormality, Ocular Hypertension, Open Angle Glaucoma
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1977 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Corneal Endothelial Dystrophy
- Interventions
- TTHX1114
- Drug
- Lead sponsor
- Trefoil Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Washington, Missouri
- Conditions
- Corneal Edema Secondary to Corneal Endothelial Dystrophy
- Interventions
- DSAEK, Anterior Segment Optical Coherence Topography (OCT), Best Spectacle Corrected Visual Acuity (BSCVA)
- Procedure · Diagnostic Test
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Corneal Edema, Corneal Endothelial Dysfunction, Corneal Endothelial Dystrophy, Fuchs Dystrophy, Fuchs Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy, Bullous Keratopathy, Endothelial Dysfunction, Moderate Corneal Endothelial Decompensation
- Interventions
- EO2002, EO2002 low dose, EO2002 mid dose, EO2002 high dose
- Biological
- Lead sponsor
- Emmecell
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 8
- States / cities
- Greater Los Angeles, California • San Diego, California • Miami, Florida + 5 more
- Conditions
- Inflammation, Uveitis
- Interventions
- Fluocinolone Acetonide 0.59 mg, Fluocinolone Acetonide 2.1 mg
- Procedure
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Cystoid Macular Edema, Fuchs Dystrophy
- Interventions
- Optical Coherence Tomography
- Diagnostic Test
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Retinal Detachment, Epiretinal Membrane, Macular Hole, Fuchs Endothelial Dystrophy
- Interventions
- Not listed
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 750 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Fuchs' Endothelial Dystrophy, Fuchs Dystrophy, Fuchs
- Interventions
- TTHX1114(NM141)
- Drug
- Lead sponsor
- Trefoil Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 11
- States / cities
- Long Beach, California • Petaluma, California • Deerfield Beach, Florida + 8 more
- Conditions
- Fuchs' Endothelial Dystrophy, Cataract
- Interventions
- Netarsudil 0.02% Ophthalmic Solution
- Drug
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 50 Years to 70 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Corneal Endothelial Cell Loss, Ocular Pain, Ocular Inflammation, Cataract Surgery
- Interventions
- Vehicle Ophthalmic Solution, Omaveloxolone Ophthalmic Suspension 0.5%, Omaveloxolone Ophthalmic Suspension 1%
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 307 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 15
- States / cities
- Laguna Hills, California • Lancaster, California • Cape Coral, Florida + 11 more
- Conditions
- Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
- Interventions
- pegaptanib sodium injection
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2019
- U.S. locations
- 4
- States / cities
- Murrieta, California • Marshalltown, Iowa • West Mifflin, Pennsylvania + 1 more
- Conditions
- Corneal and Endothelial Cell Measurements
- Interventions
- Not listed
- Lead sponsor
- Nidek Co. LTD.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2012
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Fuchs' Endothelial Dystrophy, Bullous Keratopathy
- Interventions
- Netarsudil, Placebo
- Drug
- Lead sponsor
- Cornea Research Foundation of America
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Fuchs' Endothelial Corneal Dystrophy
- Interventions
- Wearing of contact lens
- Device
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Fuchs' Endothelial Dystrophy
- Interventions
- Amphotericin B
- Drug
- Lead sponsor
- Cornea Research Foundation of America
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Fuchs' Endothelial Dystrophy
- Interventions
- Netarsudil, Placebo
- Drug
- Lead sponsor
- Price Vision Group
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Uveitis, Posterior
- Interventions
- Retisert, Fluocinolone Acetonide Intravitreal Implant
- Device · Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 12 Years to 80 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Fuchs Dystrophy, Pseudophakic Bullous Keratopathy
- Interventions
- Not listed
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Fuchs' Endothelial Dystrophy, Corneal Edema
- Interventions
- Endothelial keratoplasty, PRGF
- Procedure · Biological
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Miami, Florida • Indianapolis, Indiana
- Conditions
- Corneal Edema
- Interventions
- Netarsudil Ophthalmic
- Drug
- Lead sponsor
- Aerie Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 12
- States / cities
- Garden Grove, California • Laguna Hills, California • Edgewood, Kentucky + 9 more